Serina Therapeutics, Inc.

SER

Healthcare|Biotechnology|US

$1.38

-0.27 (-16.36%)

DCF Value

$0.10

Tangible Book / Share

$1.14

Cash / Share

$1.41

About

Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.

Stock Price

-66.5%(1Y)

-31.3%

-42.5%

-21.1%

YTD

-27.7%

-65.4%

-93.6%

-95.3%

Pipeline Summary

2 total trials

Phase 1

Phase 2

Phase 3

Phase 4

Recruiting: 1Unknown: 1

Active Trials (1)

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations

NCT07422675PARKINSON DISEASE (Disorder)

Phase 1Recruiting

Enrollment: 40 participants

Key Facts

Market Cap$20.7M

Employees16 (+23% YoY)

CEOSteven A. Ledger

IPO DateNov 28, 2018

Beta0.03

52-Week Range$1.14 – $4.45

Avg Volume65,628

ExchangeAMEX

Websiteserinatx.com

Ownership

Float13.3%

Shares Outstanding15.0M

Recent Insider Trades

Simon FarrellAWARD

Jul 22, 202630,500 shares @ $2.17

Simon FarrellOTHER

Jul 22, 20260 shares

Brannan Stephen K.BUY

Jul 7, 20261,000 shares @ $2.03

Venkatesan JayCONVERSION

Jun 17, 2026224,152 shares @ $2.25

Venkatesan JayAWARD

Jun 17, 202615,250 shares @ $1.98

Peers

ALGSAligos Therapeutics, Inc.

$25.4M

BRNSBarinthus Biotherapeutics plc

$30.2M

CVMCEL-SCI Corporation

$25.5M

GNTAGenenta Science S.p.A.

$18.0M

GRCEGrace Therapeutics, Inc.

$30.1M

INMBINmune Bio, Inc.

$31.4M

JUNSJupiter Neurosciences, Inc.

$2.9M

SKYESkye Bioscience, Inc.

$4.4M

Recent News

Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC)

Nov 4, 2026 · globenewswire.com

Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients

Nov 3, 2026 · globenewswire.com

Custom Truck One Source, Inc. Reports Record Third Quarter 2026 Results and Increases Full Year 2026 Adjusted EBITDA and SER Revenue Guidance

Oct 26, 2026 · businesswire.com

Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026

Oct 15, 2026 · globenewswire.com

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson's Disease: Serina Discusses SER-252's Clinical Progress"

Sep 23, 2026 · globenewswire.com

Data last updated: Nov 9, 2026, 04:33 AM